AU784359B2 - Compositions and methods for inhibiting endothelial cell proliferation - Google Patents

Compositions and methods for inhibiting endothelial cell proliferation Download PDF

Info

Publication number
AU784359B2
AU784359B2 AU30748/01A AU3074801A AU784359B2 AU 784359 B2 AU784359 B2 AU 784359B2 AU 30748/01 A AU30748/01 A AU 30748/01A AU 3074801 A AU3074801 A AU 3074801A AU 784359 B2 AU784359 B2 AU 784359B2
Authority
AU
Australia
Prior art keywords
hgf
angiogenesis
cells
fragments
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU30748/01A
Other languages
English (en)
Other versions
AU3074801A (en
Inventor
Clara Dey
Hong Liang
Kim Lee Sim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Casi Pharmaceuticals Inc
Original Assignee
Entremed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Entremed Inc filed Critical Entremed Inc
Publication of AU3074801A publication Critical patent/AU3074801A/en
Application granted granted Critical
Publication of AU784359B2 publication Critical patent/AU784359B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU30748/01A 1999-12-15 2000-12-15 Compositions and methods for inhibiting endothelial cell proliferation Ceased AU784359B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US17100799P 1999-12-15 1999-12-15
US60/171007 1999-12-15
US19356600P 2000-03-31 2000-03-31
US60/193566 2000-03-31
PCT/US2000/034039 WO2001044294A2 (fr) 1999-12-15 2000-12-15 Compositions et procedes d'inhibition de la proliferation de cellules endotheliales

Publications (2)

Publication Number Publication Date
AU3074801A AU3074801A (en) 2001-06-25
AU784359B2 true AU784359B2 (en) 2006-03-16

Family

ID=26866643

Family Applications (1)

Application Number Title Priority Date Filing Date
AU30748/01A Ceased AU784359B2 (en) 1999-12-15 2000-12-15 Compositions and methods for inhibiting endothelial cell proliferation

Country Status (5)

Country Link
EP (1) EP1242451A2 (fr)
JP (1) JP2003517007A (fr)
AU (1) AU784359B2 (fr)
CA (1) CA2394167A1 (fr)
WO (1) WO2001044294A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1320384B1 (fr) * 2000-08-28 2007-10-10 Damavand Wound AB Effets synergiques du facteur de croissance des hepatocytes et traitement antibacterien
AU8591901A (en) 2000-09-05 2002-03-22 Karolinska Innovations Ab Materials and methods relating to endothelial cell growth inhibitors
US20070225218A1 (en) * 2001-06-29 2007-09-27 Delegeane Angelo M Extracellular Messengers
FR2831540B1 (fr) * 2001-10-31 2004-07-09 Inst Vaisseaux Et Du Sang Peptide isole du facteur de croissance hepatocytaire et ses variants, procede de preparation et utilisation en therapeutique en tant qu'agents antiangiogeniques
WO2004019991A2 (fr) * 2002-08-30 2004-03-11 F. Hoffmann-La Roche Ag Antagoniste nk4 du facteur de croissance de l'hepatocyte/du facteur de dispersion pour le traitement de gliome
JP2004123650A (ja) * 2002-10-04 2004-04-22 Medgel Corp Ｎｋ４を含有する徐放性製剤
US20070224703A1 (en) * 2003-09-29 2007-09-27 Fariba Nayeri Rapid Determination of Hepatocyte Growth Factor (Hgf) in the Body Fluids
EP1863519B1 (fr) * 2005-03-31 2013-09-25 The General Hospital Corporation Modulation de hgf/hgfr pour traiter un lymphoedème
ATE517126T1 (de) * 2006-03-20 2011-08-15 Seikagaku Kogyo Co Ltd Therapeutikum für rheumatoide arthritis
JP5530635B2 (ja) * 2007-02-14 2014-06-25 独立行政法人科学技術振興機構 腸管癒着抑制剤
JP2009091339A (ja) * 2007-10-12 2009-04-30 Seikagaku Kogyo Co Ltd 関節リウマチの処置剤
CN102336812B (zh) * 2010-07-28 2015-12-02 上海市第一人民医院 一种具有抑制血管生成活性的多肽

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0890361A1 (fr) * 1995-10-24 1999-01-13 NAKAMURA, Toshikazu Agent antitumoral

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3438888B2 (ja) * 1990-09-14 2003-08-18 アメリカ合衆国 非分裂促進競合性ｈｇｆ拮抗剤
DK0869970T3 (da) * 1995-12-13 2004-07-05 Abbott Lab Endothelcelleprolifereringsinhibitor og dens anvendelse
US5801146A (en) * 1996-05-03 1998-09-01 Abbott Laboratories Compound and method for inhibiting angiogenesis
US6107473A (en) * 1997-10-01 2000-08-22 Smithkline Beecham Corporation Kringle-related clone HTHBZ47
GB9815505D0 (en) * 1998-07-16 1998-09-16 Adprotech Plc Polypeptide derivatives
WO2000044391A2 (fr) * 1999-01-28 2000-08-03 The Children's Medical Center Corporation Fragments de region kringle 4 de plasminogene et procedes d'utilisation
WO2000061179A1 (fr) * 1999-04-14 2000-10-19 Karolinska Innovations Ab Domaines kringle du plasminogene capables de moduler l'angiogenese in vivo

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0890361A1 (fr) * 1995-10-24 1999-01-13 NAKAMURA, Toshikazu Agent antitumoral

Also Published As

Publication number Publication date
EP1242451A2 (fr) 2002-09-25
JP2003517007A (ja) 2003-05-20
CA2394167A1 (fr) 2001-06-21
AU3074801A (en) 2001-06-25
WO2001044294A2 (fr) 2001-06-21
WO2001044294A3 (fr) 2002-02-07

Similar Documents

Publication Publication Date Title
US6544947B2 (en) Compositions and methods for inhibiting endothelial cell proliferation and regulating angiogenesis using cancer markers
US7485439B2 (en) Nucleic acids encoding plasminogen fragments and methods of use
KR100336452B1 (ko) 앤지오스타틴및맥관형성억제를위한이의사용방법
CA2219081C (fr) Fragments d'angiostatine et angiostatine en agregat et methodes d'utilisation
AU784359B2 (en) Compositions and methods for inhibiting endothelial cell proliferation
JP2001518304A (ja) アンギオスタチン成分を含む融合タンパク質及び抗腫瘍療法におけるその使用
CA2240296C (fr) Inhibiteur de la proliferation des cellules endotheliales, et procede d'utilisation de celui-ci
US20040253226A1 (en) Compositions and methods for inhibiting endothelial cell proliferation and regulating angiogenesis using serine proteases
US20040121945A1 (en) Compositions and methods for inhibiting endothelial cell proliferation
WO2000061179A1 (fr) Domaines kringle du plasminogene capables de moduler l'angiogenese in vivo
CA2360690A1 (fr) Fragments de region kringle 4 de plasminogene et procedes d'utilisation
US7241446B2 (en) Methods for modulating angiogenesis via VEGF
CA2361334C (fr) Fragments deglycosyles des regions kringle 1-3 de plasminogene et methodes d'utilisation
EP1268798B1 (fr) Propriétés anti-angiogéniques de la proteine vascostatin et fragments et variants de celui-ci
AU2001287274B2 (en) Anti-angiogenic and anti-tumor properties of vascostatin and other nidogen domains
US7629146B2 (en) Truncated 24kDa basic fibroblast growth factor
KR19990008029A (ko) 안기오스타틴 단편과 안기오스타틴 응집체 및 이의 이용방법
AU2001287274A1 (en) Anti-angiogenic and anti-tumor properties of vascostatin and other nidogen domains
MXPA99011041A (en) Angiostatin fragments and method of use